Literature DB >> 11355948

The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.

A Paju1, T Sorsa, T Tervahartiala, E Koivunen, C Haglund, A Leminen, T Wahlström, T Salo, U H Stenman.   

Abstract

Proteolysis mediated by matrix metalloproteinases (MMPs) and serine proteinases is associated with cancer invasion and metastasis. Activation of latent proMMPs, and especially the proforms of the type IV collagen degrading gelatinases A and B (proMMP-2 and proMMP-9), is thought to be a critical step in this process. We have recently found that human tumour-associated trypsin-2 is a potent activator of proMMP-9 and it also activates proMMP-2 in vitro. Trypsinogen, MMP-2, and MMP-9 are expressed in ovarian cancer. To elucidate the function of trypsin in vivo, we studied whether high concentrations of trypsinogen-1, trypsinogen-2, their alpha(1)-proteinase inhibitor (API) complexes, and tumour-associated trypsin inhibitor (TATI) are associated with proMMP-2 and proMMP-9 activation in ovarian tumour cyst fluids. Zymography and immunofluorometric analysis of 61 cyst fluids showed a significant association between high trypsin concentrations and the activation of MMP-9 (P = 0.003-0.05). In contrast, the trypsin concentrations were inversely associated with the activation of MMP-2 (P = 0.01-0.02). Immunohistochemical analysis of ovarian tumour tissue demonstrated expression of trypsinogen-2 and TATI in the secretory epithelium. MMP-2 was detected both in stromal and epithelial cells whereas MMP-9 was detected in neutrophils and macrophage-like cells in stromal and epithelial areas. These results suggest that trypsin may play a role in the regulation of the MMP-dependent proteolysis associated with invasion and metastasis of ovarian cancer. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355948      PMCID: PMC2363633          DOI: 10.1054/bjoc.2001.1806

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  55 in total

1.  Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2).

Authors:  A Westerlund; E Hujanen; U Puistola; T Turpeenniemi-Hujanen
Journal:  Gynecol Oncol       Date:  1997-10       Impact factor: 5.482

2.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

3.  Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury.

Authors:  G Ferry; M Lonchampt; L Pennel; G de Nanteuil; E Canet; G C Tucker
Journal:  FEBS Lett       Date:  1997-02-03       Impact factor: 4.124

4.  Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.

Authors:  S Afzal; W D Foulkes; B Boyce; S Tickle; M R Cardillo; T Baker; M Pignatelli; G W Stamp
Journal:  Lab Invest       Date:  1996-02       Impact factor: 5.662

5.  MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.

Authors:  S Afzal; E N Lalani; R Poulsom; A Stubbs; G Rowlinson; H Sato; M Seiki; G W Stamp
Journal:  Hum Pathol       Date:  1998-02       Impact factor: 3.466

6.  Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors.

Authors:  F Hirahara; E Miyagi; Y Nagashima; Y Miyagi; H Yasumitsu; N Koshikawa; Y Nakatani; T Nakazawa; K Udagawa; H Kitamura; H Minaguchi; K Miyazaki
Journal:  Gynecol Oncol       Date:  1998-02       Impact factor: 5.482

7.  Activation of type IV procollagenases by human tumor-associated trypsin-2.

Authors:  T Sorsa; T Salo; E Koivunen; J Tyynelä; Y T Konttinen; U Bergmann; A Tuuttila; E Niemi; O Teronen; P Heikkilä; H Tschesche; J Leinonen; S Osman; U H Stenman
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

8.  Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.

Authors:  D A Fishman; L M Bafetti; S Banionis; A S Kearns; K Chilukuri; M S Stack
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

9.  72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.

Authors:  M De Nictolis; S Garbisa; G Lucarini; G Goteri; L Masiero; A Ciavattini; G G Garzetti; W G Stetler-Stevenson; G Fabris; G Biagini; J Prat
Journal:  Int J Gynecol Pathol       Date:  1996-04       Impact factor: 2.762

10.  92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer.

Authors:  B S Nielsen; S Timshel; L Kjeldsen; M Sehested; C Pyke; N Borregaard; K Danø
Journal:  Int J Cancer       Date:  1996-01-03       Impact factor: 7.396

View more
  10 in total

1.  Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development.

Authors:  Ulf-Håkan Stenman
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

2.  Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery.

Authors:  Maija Piekkala; Jaana Hagström; Maarit Tanskanen; Risto Rintala; Caj Haglund; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

3.  Matrix metalloprotein-9 activation under cell-to-cell interaction between endothelial cells and monocytes: possible role of hypoxia and tumor necrosis factor-α.

Authors:  Yuko Yamamoto; Tomohiro Osanai; Fumie Nishizaki; Takanori Sukekawa; Kei Izumiyama; Shigeki Sagara; Ken Okumura
Journal:  Heart Vessels       Date:  2012-01-11       Impact factor: 2.037

4.  Comparative study of the binding between chlorogenic acid and four proteins by isothermal titration calorimetry, spectroscopy and docking methods.

Authors:  Miao Zhang; Ning Zhang; Xinluan Lu; Wenjin Li; Ruiyong Wang; Junbiao Chang
Journal:  Pharmacol Rep       Date:  2022-05-11       Impact factor: 3.024

5.  A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer.

Authors:  Hatem A El-mezayen; Fatheya M Metwally; Hossam Darwish
Journal:  Tumour Biol       Date:  2013-11-13

6.  An aMMP-8 Point-of-Care and Questionnaire Based Real-Time Diagnostic Toolkit for Medical Practitioners.

Authors:  Ismo T Räisänen; Hanna Lähteenmäki; Shipra Gupta; Andreas Grigoriadis; Vaibhav Sahni; Juho Suojanen; Hanna Seppänen; Taina Tervahartiala; Dimitra Sakellari; Timo Sorsa
Journal:  Diagnostics (Basel)       Date:  2021-04-15

Review 7.  The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.

Authors:  Cailin O'Connell; Sabrina VandenHeuvel; Aparna Kamat; Shreya Raghavan; Biana Godin
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

8.  Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells.

Authors:  Mohammad K Ghalayini; Qihan Dong; Des R Richardson; Stephen J Assinder
Journal:  Biosci Rep       Date:  2013-06-11       Impact factor: 3.840

9.  MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.

Authors:  Kati Räsänen; Kien X Dang; Harri Mustonen; Tho H Ho; Susanna Lintula; Hannu Koistinen; Ulf-Håkan Stenman; Caj Haglund; Jakob Stenman
Journal:  Mol Oncol       Date:  2017-12-27       Impact factor: 6.603

10.  Active MMP-8 point-of-care (PoC)/chairside enzyme-test as an adjunctive tool for early and real-time diagnosis of peri-implantitis.

Authors:  Hanna Lähteenmäki; Taina Tervahartiala; Ismo T Räisänen; Pirjo Pärnänen; Matti Mauramo; Shipra Gupta; Victoria Sampson; Nilminie Rathnayake; Anna-Maria Heikkinen; Saeed Alassiri; Dirk-Rolf Gieselmann; Roland Frankenberger; Timo Sorsa
Journal:  Clin Exp Dent Res       Date:  2022-02-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.